A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms
Status:
Unknown status
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-523
in Patients With Relapsed or Refractory Mature B-cell Neoplasms